RxDoctor Payments Data

Claudio Bernaschina Bobadilla, MD

Urology · Ponce, PRNPI 1922197011

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $102,113 of the $131,687 with a category attached, or 77.5%. 20 manufacturers reported payments, led by Verity Pharmaceuticals Inc. at 49.4% of the total. Among urology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$131,687in general payments, 2019–2025

Across 190 payments — averaging $693.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verity Pharmaceuticals Inc.$65K
  • Teleflex LLC$52K
  • AbbVie$6K
  • Boston Scientific$3K
  • Johnson & Johnson$2K
  • Neotract Inc.$1K
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$18,58514%
  • Speaking & faculty fees$102,11378%
  • Travel & lodging$4,9484%
  • Food & beverage$5,5604%
  • Education$4820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,687 in reported general payments places this provider in the 95th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$36,860
Medicare patients
56
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide158$2,261,629
ErleadaApalutamide130$1,935,565
MyrbetriqMirabegron174$134,218
ElmironPentosan Polysulfate Sodium13$14,340
Tamsulosin Hcl645$11,191
Testosterone42$7,679
Estradiol80$6,356
Finasteride168$3,364
Alfuzosin Hcl ErAlfuzosin Hcl130$3,233
Bethanechol Chloride20$3,095
Oxybutynin Chloride ErOxybutynin Chloride101$2,730
Tolterodine Tartrate ErTolterodine Tartrate22$2,695
Abiraterone Acetate13$2,544
Sildenafil Citrate142$2,474
Potassium Citrate ErPotassium Citrate46$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$199$2,395,847332 claims
Johnson & JohnsonErleada$1,866$1,935,565130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 122 urology providers in Puerto Rico.

Other urology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →